
Novo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI Partner as Stock Surges 25%
Novo Nordisk posted strong Q1 2026 earnings and saw its stock rise 25% over 30 days after pivoting to a licensing-first model in cell therapy. The Danish pharma giant shut its internal cell therapy unit and handed Parkinson's disease development to Cellular Intelligence, an AI-platform company. The move reflects a broader European shift toward AI-native drug discovery infrastructure.



























